S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
NASDAQ:LMNL

Liminal BioSciences (LMNL) Stock Forecast, Price & News

$0.52
-0.07 (-11.89%)
(As of 05/23/2022 04:00 PM ET)
Add
Compare
Today's Range
$0.50
$0.59
50-Day Range
$0.52
$1.04
52-Week Range
$0.37
$6.30
Volume
86,059 shs
Average Volume
61,773 shs
Market Capitalization
$16.14 million
P/E Ratio
0.66
Dividend Yield
N/A
Beta
1.57
30 days | 90 days | 365 days | Advanced Chart
Receive LMNL News and Ratings via Email

Sign-up to receive the latest news and ratings for Liminal BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Liminal BioSciences logo

About Liminal BioSciences

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

Headlines

Liminal BioSciences reports Q1 results
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LMNL
Employees
251
Year Founded
N/A

Sales & Book Value

Annual Sales
$510 thousand
Book Value
$0.59 per share

Profitability

Net Income
$10.28 million
Net Margins
3,107.45%
Pretax Margin
-8,338.08%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$16.14 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/17/2022
Today
5/23/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.79 out of 5 stars

Medical Sector

930th out of 1,416 stocks

Pharmaceutical Preparations Industry

466th out of 677 stocks

Analyst Opinion: 3.0Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -













Liminal BioSciences (NASDAQ:LMNL) Frequently Asked Questions

Is Liminal BioSciences a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Liminal BioSciences in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Liminal BioSciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LMNL, but not buy additional shares or sell existing shares.
View analyst ratings for Liminal BioSciences
or view top-rated stocks.

When is Liminal BioSciences' next earnings date?

Liminal BioSciences is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Liminal BioSciences
.

How were Liminal BioSciences' earnings last quarter?

Liminal BioSciences Inc. (NASDAQ:LMNL) issued its quarterly earnings data on Thursday, March, 17th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.06. The company had revenue of $0.19 million for the quarter. Liminal BioSciences had a net margin of 3,107.45% and a negative trailing twelve-month return on equity of 246.63%.
View Liminal BioSciences' earnings history
.

What price target have analysts set for LMNL?

2 equities research analysts have issued 12 month price targets for Liminal BioSciences' shares. Their forecasts range from $4.50 to $11.00. On average, they anticipate Liminal BioSciences' share price to reach $7.75 in the next twelve months. This suggests a possible upside of 1,390.4% from the stock's current price.
View analysts' price targets for Liminal BioSciences
or view top-rated stocks among Wall Street analysts.

Who are Liminal BioSciences' key executives?
Liminal BioSciences' management team includes the following people:
  • Mr. Bruce Pritchard BA, CA, FIOD, Chief Exec. Officer (Age 48, Pay $805.5k)
  • Mr. Patrick Sartore, Pres (Age 47, Pay $737.7k)
  • Ms. Marie Iskra, Corp. Sec. & Gen. Counsel (Age 46, Pay $548.03k)
  • Ms. N. Nicole Rusaw C.A., CPA, Interim Chief Financial Officer
  • Shrinal Inamdar, Mang. of Investor Relations & Communications
  • Dr. Steven J. Burton, Pres of Prometic Bioseparations Ltd
  • Dr. John Bienenstock, Member of Advisory Committee - Therapeutics (Age 85)
  • Dr. Christopher L. Penney, Chief Scientific Officer of Therapeutics - ProMetic BioSciences Inc
  • Dr. Robert G. Rohwer, Member of Scientific Advisory Committee - PRDT
  • Dr. Volker Helrich, Member of Scientific Advisory Committee - Therapeutics
What other stocks do shareholders of Liminal BioSciences own?
What is Liminal BioSciences' stock symbol?

Liminal BioSciences trades on the NASDAQ under the ticker symbol "LMNL."

Who are Liminal BioSciences' major shareholders?

Liminal BioSciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include National Bank of Canada FI (0.32%), Renaissance Technologies LLC (0.11%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

Which institutional investors are selling Liminal BioSciences stock?

LMNL stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

Which institutional investors are buying Liminal BioSciences stock?

LMNL stock was bought by a variety of institutional investors in the last quarter, including National Bank of Canada FI, and Simplex Trading LLC.

How do I buy shares of Liminal BioSciences?

Shares of LMNL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Liminal BioSciences' stock price today?

One share of LMNL stock can currently be purchased for approximately $0.52.

How much money does Liminal BioSciences make?

Liminal BioSciences has a market capitalization of $16.14 million and generates $510 thousand in revenue each year. The company earns $10.28 million in net income (profit) each year or $0.79 on an earnings per share basis.

How many employees does Liminal BioSciences have?

Liminal BioSciences employs 251 workers across the globe.

What is Liminal BioSciences' official website?

The official website for Liminal BioSciences is www.liminalbiosciences.com.

How can I contact Liminal BioSciences?

Liminal BioSciences' mailing address is 440 Armand-Frappier Boulevard Suite 300, Laval A8, H7V 4B4. The company can be reached via phone at 1-450-781-0115, via email at [email protected], or via fax at 1-450-781-4477.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.